Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Parakkal Deepak, Quazim A. Alayo, Aava Khatiwada, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 8, pp. 1592-1601.e3
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy
Xiaohua Pan, Qing Zhu, Li‐Long Pan, et al.
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108176-108176
Closed Access | Times Cited: 118
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Immunological Reviews (2024) Vol. 322, Iss. 1, pp. 98-112
Open Access | Times Cited: 29
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Pablo A. Olivera, Stéphane Zuily, Paulo Gustavo Kotze, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 12, pp. 857-873
Open Access | Times Cited: 104
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Quazim A. Alayo, Marc Fenster, Osama Altayar, et al.
Crohn s & Colitis 360 (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 60
Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease
Idoia Busnadiego, Irène A. Abela, Pascal M. Frey, et al.
PLoS Biology (2022) Vol. 20, Iss. 7, pp. e3001709-e3001709
Open Access | Times Cited: 52
Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management
Viviana Laredo, Sandra G. García, Samuel J. Martínez‐Domínguez, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 871-871
Open Access | Times Cited: 40
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
Sarina B. Elmariah, Jeffrey S. Smith, Joseph F. Merola
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 427-431
Closed Access | Times Cited: 39
Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy
Olga Maria Nardone, Irene Zammarchi, Giovanni Santacroce, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2389-2389
Open Access | Times Cited: 30
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure
Julián Panés, Geert R. D’Haens, Bruce E. Sands, et al.
United European Gastroenterology Journal (2024) Vol. 12, Iss. 6, pp. 793-801
Open Access | Times Cited: 16
Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis
Brad D. Constant, Robert N. Baldassano, Jacqueline Kirsch, et al.
Journal of Pediatric Gastroenterology and Nutrition (2022) Vol. 75, Iss. 6, pp. 724-730
Closed Access | Times Cited: 30
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
Eleanor Liu, Nasar Aslam, Gaurav Nigam, et al.
Drugs in Context (2022) Vol. 11, pp. 1-17
Open Access | Times Cited: 29
Can we change the natural course of inflammatory bowel disease?
Catherine Le Berre, Silvio Danese, Laurent Peyrin‐Biroulet
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 21
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1231-1248
Open Access | Times Cited: 20
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
Chrysoula G. Gialouri, Savvina Moustafa, Κonstantinos Thomas, et al.
Rheumatology International (2023) Vol. 43, Iss. 3, pp. 421-435
Open Access | Times Cited: 19
Management of inflammatory bowel disease in the elderly: A review
Paula Sousa, Lorenzo Bertani, Cláudio Rodrigues
Digestive and Liver Disease (2023) Vol. 55, Iss. 8, pp. 1001-1009
Open Access | Times Cited: 17
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice
Rupa Banerjee, Vishal Sharma, Rajendra Patel, et al.
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 22-35
Closed Access | Times Cited: 7
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis
Christopher Ma, Remo Panaccione, Yasi Xiao, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 5, pp. 861-871
Open Access | Times Cited: 28
Inflammatory Bowel Disease Is Associated With an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank
Quazim A. Alayo, Edward V. Loftus, Andrés Yarur, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 3, pp. 761-770.e13
Closed Access | Times Cited: 24
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Axel Dignaß, Marla C. Dubinsky, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 8, pp. 1270-1280
Open Access | Times Cited: 6
Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future
Manish Manrai, Atul Jha, Saurabh Dawra, et al.
Future Pharmacology (2024) Vol. 4, Iss. 1, pp. 279-316
Open Access | Times Cited: 5
Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
Danny Con, Bridgette Andrew, Steven Nicolaides, et al.
Intestinal Research (2021) Vol. 20, Iss. 1, pp. 101-113
Open Access | Times Cited: 32
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
Laura Lucaciu, Nathan Constantine‐Cooke, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 29
User's guide to JAK inhibitors in inflammatory bowel disease
Ted A. Spiewak, Anish Patel
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100096-100096
Open Access | Times Cited: 20
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander Bodelier, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 1, pp. 117-126
Open Access | Times Cited: 20
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
María Chaparro, Diana Acosta, Cristina Rodríguez, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 7, pp. 1237-1247
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top